Difference between revisions of "Non-small cell lung cancer, MET-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 15: Line 15:
 
*'''2022:''' Singh et al. [https://doi.org/10.1200/jco.22.00824 Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline]
 
*'''2022:''' Singh et al. [https://doi.org/10.1200/jco.22.00824 Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline]
 
=Metastatic disease, all lines of therapy=
 
=Metastatic disease, all lines of therapy=
−
 
 
==Capmatinib monotherapy {{#subobject:791280|Regimen=1}}==
 
==Capmatinib monotherapy {{#subobject:791280|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:f3e479|Variant=1}}===
 
===Regimen {{#subobject:f3e479|Variant=1}}===
 
{| class="wikitable" style="color:white; background-color:#404040"
 
{| class="wikitable" style="color:white; background-color:#404040"
Line 29: Line 28:
 
|-
 
|-
 
|[https://doi.org/10.1056/nejmoa2002787 Wolf et al. 2020 (GEOMETRY mono-1)]
 
|[https://doi.org/10.1056/nejmoa2002787 Wolf et al. 2020 (GEOMETRY mono-1)]
−
|NR
+
{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
 +
|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-233-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
 +
|-
 +
|}
 +
|2015-NR
 
|style="background-color:#91cf61"|Phase 2 (RT)
 
|style="background-color:#91cf61"|Phase 2 (RT)
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
 
*MET exon 14 skipping alterations
 
*MET exon 14 skipping alterations
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food
 
*[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food
−
 
 
'''Continued indefinitely'''
 
'''Continued indefinitely'''
−
 
+
</div></div>
 
===References===
 
===References===
 
<!-- # '''Abstract:''' Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004 link to abstract] '''contains dosing details in manuscript''' [https://doi.org/10.1200/JCO.2019.37.15_suppl.9004 DOI] -->
 
<!-- # '''Abstract:''' Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004 link to abstract] '''contains dosing details in manuscript''' [https://doi.org/10.1200/JCO.2019.37.15_suppl.9004 DOI] -->
 
#'''GEOMETRY mono-1:''' Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. [https://doi.org/10.1056/nejmoa2002787 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/32877583 PubMed] NCT02414139
 
#'''GEOMETRY mono-1:''' Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. [https://doi.org/10.1056/nejmoa2002787 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/32877583 PubMed] NCT02414139
−
 
 
==Tepotinib monotherapy {{#subobject:7it980|Regimen=1}}==
 
==Tepotinib monotherapy {{#subobject:7it980|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:f3eig9|Variant=1}}===
 
===Regimen {{#subobject:f3eig9|Variant=1}}===
 
{| class="wikitable" style="width: 60%; text-align:center;"  
 
{| class="wikitable" style="width: 60%; text-align:center;"  
Line 58: Line 62:
 
|}
 
|}
 
''Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.''
 
''Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.''
 +
<div class="toccolours" style="background-color:#fdcdac">
 
====Biomarker eligibility criteria====
 
====Biomarker eligibility criteria====
 
*MET exon 14 skipping alterations
 
*MET exon 14 skipping alterations
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Tepotinib (Tepmetko)]] 500 mg PO once per day
 
*[[Tepotinib (Tepmetko)]] 500 mg PO once per day
−
 
 
'''Continued indefinitely'''
 
'''Continued indefinitely'''
−
 
+
</div></div>
 
===References===
 
===References===
 
#'''VISION<sub>NSCLC</sub>:''' Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. [https://doi.org/10.1056/nejmoa2004407 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32469185 PubMed] NCT02864992
 
#'''VISION<sub>NSCLC</sub>:''' Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. [https://doi.org/10.1056/nejmoa2004407 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32469185 PubMed] NCT02864992
−
 
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Non-small cell lung cancers]]
 
[[Category:Non-small cell lung cancers]]

Revision as of 01:09, 24 February 2023

Back to Top

Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page
3 variants on this page


Guidelines

ASCO

Metastatic disease, all lines of therapy

Capmatinib monotherapy

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Wolf et al. 2020 (GEOMETRY mono-1)
ESMO-MCBS (3)
2015-NR Phase 2 (RT)

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains dosing details in abstract PubMed NCT02414139

Tepotinib monotherapy

Regimen

Study Years of enrollment Evidence
Paik et al. 2020 (VISIONNSCLC) 2016-2020 Phase 2 (RT)

Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. VISIONNSCLC: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains dosing details in manuscript PubMed NCT02864992
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_MET-mutated&oldid=66395"